SlideShare a Scribd company logo
ABG ( ARTERIAL BLOOD GAS
)
HIMANSHUARORA
ABG ( Arterial blood gass)
◦ ABG – Arterial blood gases, which are present in the blood is called arterial blood gases for eg
CO2, O2, SPo2. PH etc.
◦ An arterial-blood gas (ABG) test measures the amounts of arterial gases, such as Oxygen,
carbondioxide, PH, bicarbonate and saturated oxygen .
◦ An ABG test requires that a small volume of blood be drawn from the radial artery because it is
easily accessible, can be compressed to control bleeding . The selection of which radial artery
to draw from is based on the outcome of an Allen's test.
◦ Other arteries for withdrawIng of blood are – Dorsalis pedis, Femoral and brachial artery.
Procedure
◦ Required equipment
◦ Gloves
◦ Apron
◦ Pre-heparinised arterial blood gas syringe .
◦ Arterial blood gas needle (23 G)
◦ Alcohol wipe (70% isopropyl)
◦ Gauze or cotton wool
◦ Tape
◦ Lidocaine 1% (1 mL)
◦ Subcutaneous needle .
◦ Check for any contraindications to arterial blood gas sampling:
◦ Absolute contraindications: peripheral vascular disease in the limb, cellulitis surrounding the
site or arteriovenous fistula.
◦ Relative contraindications: impaired coagulation (e.g. anticoagulation therapy, liver disease,
low platelets <50).
◦ Check if the patient has an allergy to local anaesthetic (e.g. lidocaine).
◦ Position the patient so that they are sitting comfortably, ideally with their wrist supported by a
pillow. If a bed is available, the patient can lay down for the procedure (this is sometimes
preferable, particularly if the patient is prone to vasovagal syncope).
◦ Ask the patient if they have any pain before continuing with the clinical procedure.
◦ Then choose the appropriate artery, if radial artery will be choosen then need to perform a
simple test for better outcome.
◦ Allen test is a medical sign used in physical examination of arterial blood flow to the
hands.
◦ The original test proposed by Allen is performed as follows:
◦ The patient is asked to clench both fists tightly for 1 minute at the same time.
◦ Pressure is applied over both radial arteries simultaneously so as to occlude them.
◦ The patient then opens the fingers of both hands rapidly, and the examiner compares
the colour of both. The initial pallor should be replaced quickly by rubor.
Indication
◦ 1) Respiratory failure. And assess its severity.
◦ 2) To monitor the patient on ventilator and assist weaning.
◦ 3) To Measure the acid-base level in the blood of people who are have heart
failure, kidney failure, uncontrolled diabetes, sleep disorders, severe infections, or
after a drug overdose.
◦ 4) Severe metabolic disturbance e.g. diabetic ketoacidosis
◦ 5) All critically ill patients.
Parameters for ABG test
◦ 1) PH 7.35 to 7.45 in which from 7.35 to 7.39 is acidic and from 7.40 to 7.45 basic.
◦ 2) PCO2 35 to 45 mmhg
◦ 3) PO2 80 to 100 mmhg
◦ 4) SPO2 >90%
◦ 5) Bicarbonates 22 to 28 mEq/l
◦ Main 3 functions which are checked during ABG test
◦ - Respiratory function PCO2
◦ - metabolic function HCO3
◦ - Acid base balance PH.
Main 4 disorders which will be found
during ABG analysis
◦ 1 Respiratory Acidosis
◦ 2 Respiratory Alklosis
◦ 3 Metabolic Acidosis
◦ 4 Metabolic Alklosis
Interpretation.
◦ Rules
◦ If PH HCO3 PCO2
◦ Compensated Abnormal Abnormal / normal Abnormal /
Normal
◦ Partly compensated Abnormal Abnormal Abnormal
◦ Fully compensated Normal Abnormal Abnormal.
Henderson Hasselbach Equation
◦ PH ~ HCO3/ PCO2.
◦ HCO3 is metabolic component
◦ PCO2 is Respiratory component
◦ Acc. To this equation always consider abnormal values for eg. If the Hco3 is abnoraml and
the pco2 is normal then we will say that the Metabolic acidosis or alkalosis.
4 Step method
◦ Step 1 – Use PH to determine the Acidosis and Akalosis
◦ Normal value of PH id 7.35 to 7.45 If ph is > 7.45 is alkalosis
◦ If ph value <7.35 Acidosis.
◦ Step 2 Interpretation of Equation and analysis Is either uncompensated, partly or fully compensated.
◦ Step 3 Determine respiratory effect
◦ Normal value 35 to 45 mmhg if > 45 acidosis ( low ph) , <35 alkalosis high ph)
◦ Or
◦ Determine Metabolic effect
◦ Normal value 22 to 28 mEq/l If > 28 Alkalosis , <22 acidosis.
◦ Step 4 If both the metabolic and respiratory factors are abnormal then minus the abnormal value
from the normal value and considered greater one .
Solve Example
◦ PH = 7.46 Ab.
◦ Pco2 = 44.4 normal
◦ HCO3 = 31.1 Ab.
◦ Pco2 113.2 Ab.
◦ Step 1 Alkalosis
◦ Step 2 Interpretation of formula PH~HCO3/PCO2
◦ Uncompensated.
◦ Step 3 Metabolic
◦ Conclusion = Uncompensated metabolic alkalosis Hyperoxemia. ( 1)
◦ PH = 7.47
◦ PCO2 = 48 mmhg
◦ HCO3 = 32 mmol/ l
◦ PO2 = 110 mmhg
Causes of respiratory Acidosis
◦ Airway obstruction disease like
◦ COPD
◦ asthma
◦ CNS depression
◦ Neuromuscular impairment
◦ Ventilatory restriction
◦ Increased CO2 production: Due to increase intake of carbohydrates
◦ Incorrect mechanical ventilation settings
Causes of respiratory alkalosis
◦ fever, pain, fear, anxiety, CVA, cerebral edema, brain trauma, brain tumor, CNS
infection
◦ Hypoxemia or hypoxia: , low FiO2
◦ pleural effusion, pneumonia, pneumothorax, pulmonary embolus
◦ Drugs, hormones: salicylates, catecholamines, progestins
◦ Pregnancy, liver disease, sepsis, hyperthyroidism
◦ Incorrect mechanical ventilation settings
Causes of metabolic alkalosis
◦ Hypovolemia
◦ GI loss of H+
◦ Vomiting, gastric suction, diarrhea .
◦ Renal loss H+
◦ Loop and thiazide diuretics, post-hypercapnia
◦ Hypervolemia,
◦ Renal loss of H+: edematous states (heart failure, cirrhosis, nephrotic syndrome),
excess ACTH, renal artery stenosis, bicarbonate administration
Causes of metabolic acidosis
◦ Diarrhea, ileostomy, proximal colostomy .
◦ proximal RTA
◦ carbonic anhydrase inhibitor (acetazolamide)
◦ Renal tubular disease
Chronic renal disease
Distal RTA
Aldosterone inhibitors or absence
◦ Arterial blood gas (ABG) values alone don't provide enough information to diagnose a
problem. For example, they can't tell whether low levels are caused by lung or heart
problems. Arterial blood gas values are most helpful when they are reviewed with
other examinations and tests.
◦ An ABG test is often done for a person who is in the hospital because of severe injury
or illness. The test can measure how well the person's lungs and kidneys are working
and how well the body is using energy.
◦ An ABG test may be most useful when a person's breathing rate is increased or
decreased or when the person has very high blood sugar (glucose) levels, a severe
infection, or heart failure.
Extubation
◦ Removal of tracheal tube or tracheotomy tube from the trachea is termed as
Extubation.
Creteria for extubation
◦ Approach
◦ Determine disease resolution and consider other factors
◦ Identify candidates for spontaneous breathing trial
◦ Perform spontaneous breathing trial
◦ Identify candidates for extubation
◦ Extubation and post-extubation care.
DETERMINE DISEASE
RESOLUTION
◦ Begins with the resolution of respiratory failure and/or the disease that prompted initiation of
mechanical ventilation
◦ Criteria to define disease resolution are not defined
◦ A systemic approach emphasising objective surrogate markers of recovery
◦ Adequate oxygenation and gas exchange
◦ PaO2 >60mmHg on FiO2 <40%
◦ PEEP 5–8cmH2O
◦ CXR stable or improving
◦ absent or only low dose vasopressors/inotropes
◦ SBP>90mmHg.
◦ Stable cardiac rhythm
◦ No tacycardia
◦ No evidence of myocardial ischemia
◦ GCS>8 equivalent, some able to follow commands, some neither.
◦ No continuous sedative infusion or neuromuscular blockade
◦ no significant weakness (e.g. can lift head off pillow, raise arms in air for 15 seconds, clap
hands)
◦ pain controlled
No significant acidosis
◦ No electrolytes disturbance .
◦ adequate fluid status (not overloaded)
◦ abdominal pain/ distention controlled
◦ tolerating feeds
◦ Adequate hemoglobin
◦ Sepsis control.
Identify candidates for spontaneous
breathing trial
◦ Spontaneous breathing trials (SBT) are used to identify patients who are likely to fail
liberation from mechanical ventilation.
◦ SBT is a test for determining readiness to breathe without a ventilator”
◦ Ideally, during an SBT we want to observe the patient under conditions of respiratory
load that would simulate those following extubation.
◦ IDENTIFICATION OF PATIENTS SUITABLE FOR SBT
◦ Patients that pass the following daily ‘wean screen’ should undergo SBT:
◦ lung disease is stable/ resolving
◦ low FiO2 (< 50%) and PEEP (< 5-8cmH2O) requirement
◦ haemodynamic stability .
◦ able to initiate spontaneous breaths (good neuromuscular function)
◦ This indicates patients suitable for a spontaneous breathing trial, those who pass also
to be assessed for extubation.
Method
◦ SBT involves the following steps:
◦ It be conducted while the patient is still connected to the ventilator circuit.
◦ When using the ventilator a PS of 5 – 7 cmH2O and 1-5 cmH20 PEEP (so called ‘minimal
ventilator settings’) will overcome increased work of breathing through the circuit (i.e. ETT)
◦ If still on the ventilator the patient should have ‘minimal ventilator settings”
◦ Initial trial should last 30 – 120 minutes
◦ If patient is not tolerate this, then Test will be negative (But)
◦ 80% of patients who tolerate this time can be permanently removed from the ventilator
PERFORM SPONTANEOUS
BREATHING TRIAL
◦ IDENTIFY PATIENTS READY FOR TRIAL OF EXTUBATION
◦ Key questions
◦ Awake or easily rousable?
◦ Able to follow commands?
◦ Minimal volume of respiratory secretions?
◦ Intact gag and cough reflex to prevent aspiration? (absent gag is normal in many
people)
◦ Consider a cuff leak test to check for laryngeal oedema:
◦ Laryngeal edema reported in as many as 40% of prolonged intubations
◦ 5% patients experience severe upper airway obstruction following extubation
◦ can be detected by ‘cuff leak’ test
Cuff leak test
◦ The cuff leak test is used to predict risk of post-extubation stridor in intubated patients
◦ Use and interpretation of the test needs to take into account the overall context of the patient’s condition and the
management implications.
◦ Procedure
◦ Suction endotracheal and oral secretions and set the ventilator in the assist control mode with the patient receiving
volume-cycled ventilation
◦ With the cuff inflated, record displayed inspiratory and expiratory tidal volumes to see whether these are similar
◦ Deflate the cuff
◦ Directly record the expiratory tidal volume over the next six breathing cycles as the expiratory tidal volume will
reach a plateau value after a few cycles
◦ Average the three lowest values
◦ The difference between the inspiratory tidal volume (measured before the cuff was deflated) and the averaged
expiratory tidal volume (after cuff deflation) is the cuff leak volume
◦ failed cuff-leak test
◦ was defined as a leak volume of less than 110 mL, or 15.5%
◦ of exhaled volume before cuff deflation.
◦ EXTUBATION AND POST-EXTUBATION CARE
◦ Monitor closely for Laryngospasm and Post-extubation stridor — reintubation is not
always need
◦ Consider high flow nasal prongs or non-invasive ventilation to treat or prevent post-
extubation respiratory failure
Extubation failure
◦ primary types of failure.
“the inability to tolerate removal of the translaryngeal tube.
“ liberation failure is used to refer to the inability to tolerate spontaneous ventilation without
mechanical support.
Causes of failure
1) Laryngospasm
2) Postobstructive Pulmonary Edema
3) Laryngeal Edema
4) Airway injury.
Treatment of Extubation Failure
◦ The onset of respiratory distress following extubation
◦ should alert the clinician that the patient is failing extuba-
◦ tion. Hypercapnia, hypoxia, and abdominal breathing are
◦ all signs that re-intubation may be necessary. Severe post-
◦ extubation stridor and an inability to manage secretions
◦ are additional indications for re-intubation.
◦ Patients who fail extubation have an increased mortality
◦ rate compared with patients who are successfully extu-
◦ bated on the first attempt
or patients who fail their first
◦ breathing trial are not extubated. NIV has not been shown to reduce
◦ the rates of re-intubation, and it can increase mortality by
◦ delaying re-intubation.
◦ Thank you

More Related Content

Similar to ABG.pptx

Adult BLS & ACLS 2015
Adult BLS & ACLS 2015Adult BLS & ACLS 2015
Adult BLS & ACLS 2015
Subhankar Paul
 
ABG by DJ
ABG by DJABG by DJ
ABG by DJ
Dharmendra Joshi
 
017 intraoperative monitoring
017 intraoperative monitoring017 intraoperative monitoring
017 intraoperative monitoring
bothyshiri
 
physiological monitoring of a surgical patient.pptx
physiological monitoring of a surgical patient.pptxphysiological monitoring of a surgical patient.pptx
physiological monitoring of a surgical patient.pptx
kiogakimathi
 
Weaning from cpb
Weaning from cpbWeaning from cpb
Weaning from cpb
Hossam atef
 
Cardiovascular & Hematologic System
Cardiovascular & Hematologic SystemCardiovascular & Hematologic System
Cardiovascular & Hematologic System
pinoy nurze
 
Shock
Shock Shock
BCC4: Michael Parr on ICU - Surviving Trauma Guidelines
BCC4: Michael Parr on ICU - Surviving Trauma GuidelinesBCC4: Michael Parr on ICU - Surviving Trauma Guidelines
BCC4: Michael Parr on ICU - Surviving Trauma Guidelines
SMACC Conference
 
Recording of arterial blood pressure and Special circulation
Recording of arterial blood pressure and Special circulationRecording of arterial blood pressure and Special circulation
Recording of arterial blood pressure and Special circulation
kamla13
 
MONITORING IN ANAESTHESIA.pptx
MONITORING IN ANAESTHESIA.pptxMONITORING IN ANAESTHESIA.pptx
MONITORING IN ANAESTHESIA.pptx
Amin Badamosi
 
Cardiovascular & Hematologic System
Cardiovascular & Hematologic SystemCardiovascular & Hematologic System
Cardiovascular & Hematologic System
Nurse ReviewDotOrg
 
BASIC ANAESTHETIC MONITORING
BASIC ANAESTHETIC MONITORING BASIC ANAESTHETIC MONITORING
BASIC ANAESTHETIC MONITORING
HARITHANALLABOTHULA1
 
Arterial blood gases interpretation11111
Arterial blood gases interpretation11111Arterial blood gases interpretation11111
Arterial blood gases interpretation11111
Mahmoud Elnaggar
 
Arterial Blood Gas Analysis.pptx
Arterial Blood Gas Analysis.pptxArterial Blood Gas Analysis.pptx
Arterial Blood Gas Analysis.pptx
mananshroff2
 
Ghjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
GhjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggigGhjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
Ghjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
NOKHAIZHAMMAD2021BSM
 
EXERCISE TOLERENCE TEST
EXERCISE TOLERENCE TEST EXERCISE TOLERENCE TEST
EXERCISE TOLERENCE TEST
AneriPatwari
 
Acute exacerbation of COPD
Acute exacerbation of COPDAcute exacerbation of COPD
Acute exacerbation of COPD
Thomas Kurian
 
MONITORING AND TRANSPORTATION OF PATIENTS.pptx
MONITORING AND TRANSPORTATION OF PATIENTS.pptxMONITORING AND TRANSPORTATION OF PATIENTS.pptx
MONITORING AND TRANSPORTATION OF PATIENTS.pptx
dhivyaramesh95
 

Similar to ABG.pptx (20)

Open heart surgery uday
Open heart surgery udayOpen heart surgery uday
Open heart surgery uday
 
Adult BLS & ACLS 2015
Adult BLS & ACLS 2015Adult BLS & ACLS 2015
Adult BLS & ACLS 2015
 
ABG by DJ
ABG by DJABG by DJ
ABG by DJ
 
017 intraoperative monitoring
017 intraoperative monitoring017 intraoperative monitoring
017 intraoperative monitoring
 
physiological monitoring of a surgical patient.pptx
physiological monitoring of a surgical patient.pptxphysiological monitoring of a surgical patient.pptx
physiological monitoring of a surgical patient.pptx
 
Weaning from cpb
Weaning from cpbWeaning from cpb
Weaning from cpb
 
Cardiovascular & Hematologic System
Cardiovascular & Hematologic SystemCardiovascular & Hematologic System
Cardiovascular & Hematologic System
 
Shock
Shock Shock
Shock
 
BCC4: Michael Parr on ICU - Surviving Trauma Guidelines
BCC4: Michael Parr on ICU - Surviving Trauma GuidelinesBCC4: Michael Parr on ICU - Surviving Trauma Guidelines
BCC4: Michael Parr on ICU - Surviving Trauma Guidelines
 
Recording of arterial blood pressure and Special circulation
Recording of arterial blood pressure and Special circulationRecording of arterial blood pressure and Special circulation
Recording of arterial blood pressure and Special circulation
 
Acid base determination
Acid base determinationAcid base determination
Acid base determination
 
MONITORING IN ANAESTHESIA.pptx
MONITORING IN ANAESTHESIA.pptxMONITORING IN ANAESTHESIA.pptx
MONITORING IN ANAESTHESIA.pptx
 
Cardiovascular & Hematologic System
Cardiovascular & Hematologic SystemCardiovascular & Hematologic System
Cardiovascular & Hematologic System
 
BASIC ANAESTHETIC MONITORING
BASIC ANAESTHETIC MONITORING BASIC ANAESTHETIC MONITORING
BASIC ANAESTHETIC MONITORING
 
Arterial blood gases interpretation11111
Arterial blood gases interpretation11111Arterial blood gases interpretation11111
Arterial blood gases interpretation11111
 
Arterial Blood Gas Analysis.pptx
Arterial Blood Gas Analysis.pptxArterial Blood Gas Analysis.pptx
Arterial Blood Gas Analysis.pptx
 
Ghjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
GhjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggigGhjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
Ghjagjhshfjsfijgsjhgjsgjhwhuwhiwghgwgiuwhuiggig
 
EXERCISE TOLERENCE TEST
EXERCISE TOLERENCE TEST EXERCISE TOLERENCE TEST
EXERCISE TOLERENCE TEST
 
Acute exacerbation of COPD
Acute exacerbation of COPDAcute exacerbation of COPD
Acute exacerbation of COPD
 
MONITORING AND TRANSPORTATION OF PATIENTS.pptx
MONITORING AND TRANSPORTATION OF PATIENTS.pptxMONITORING AND TRANSPORTATION OF PATIENTS.pptx
MONITORING AND TRANSPORTATION OF PATIENTS.pptx
 

Recently uploaded

FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
Michel Dumontier
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Sérgio Sacani
 
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptxBody fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
muralinath2
 
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
Sérgio Sacani
 
The ASGCT Annual Meeting was packed with exciting progress in the field advan...
The ASGCT Annual Meeting was packed with exciting progress in the field advan...The ASGCT Annual Meeting was packed with exciting progress in the field advan...
The ASGCT Annual Meeting was packed with exciting progress in the field advan...
Health Advances
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
AADYARAJPANDEY1
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
AlaminAfendy1
 
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
Scintica Instrumentation
 
ESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptxESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptx
muralinath2
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
Sérgio Sacani
 
plant biotechnology Lecture note ppt.pptx
plant biotechnology Lecture note ppt.pptxplant biotechnology Lecture note ppt.pptx
plant biotechnology Lecture note ppt.pptx
yusufzako14
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
azzyixes
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
SAMIR PANDA
 
Comparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebratesComparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebrates
sachin783648
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
muralinath2
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
Sérgio Sacani
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
Lokesh Patil
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
IqrimaNabilatulhusni
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
muralinath2
 
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCINGRNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
AADYARAJPANDEY1
 

Recently uploaded (20)

FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
 
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptxBody fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
 
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...
 
The ASGCT Annual Meeting was packed with exciting progress in the field advan...
The ASGCT Annual Meeting was packed with exciting progress in the field advan...The ASGCT Annual Meeting was packed with exciting progress in the field advan...
The ASGCT Annual Meeting was packed with exciting progress in the field advan...
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
 
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
 
ESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptxESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptx
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
plant biotechnology Lecture note ppt.pptx
plant biotechnology Lecture note ppt.pptxplant biotechnology Lecture note ppt.pptx
plant biotechnology Lecture note ppt.pptx
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
 
Comparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebratesComparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebrates
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
 
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCINGRNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
 

ABG.pptx

  • 1. ABG ( ARTERIAL BLOOD GAS ) HIMANSHUARORA
  • 2. ABG ( Arterial blood gass) ◦ ABG – Arterial blood gases, which are present in the blood is called arterial blood gases for eg CO2, O2, SPo2. PH etc. ◦ An arterial-blood gas (ABG) test measures the amounts of arterial gases, such as Oxygen, carbondioxide, PH, bicarbonate and saturated oxygen . ◦ An ABG test requires that a small volume of blood be drawn from the radial artery because it is easily accessible, can be compressed to control bleeding . The selection of which radial artery to draw from is based on the outcome of an Allen's test. ◦ Other arteries for withdrawIng of blood are – Dorsalis pedis, Femoral and brachial artery.
  • 3. Procedure ◦ Required equipment ◦ Gloves ◦ Apron ◦ Pre-heparinised arterial blood gas syringe . ◦ Arterial blood gas needle (23 G) ◦ Alcohol wipe (70% isopropyl) ◦ Gauze or cotton wool ◦ Tape ◦ Lidocaine 1% (1 mL) ◦ Subcutaneous needle .
  • 4. ◦ Check for any contraindications to arterial blood gas sampling: ◦ Absolute contraindications: peripheral vascular disease in the limb, cellulitis surrounding the site or arteriovenous fistula. ◦ Relative contraindications: impaired coagulation (e.g. anticoagulation therapy, liver disease, low platelets <50). ◦ Check if the patient has an allergy to local anaesthetic (e.g. lidocaine).
  • 5. ◦ Position the patient so that they are sitting comfortably, ideally with their wrist supported by a pillow. If a bed is available, the patient can lay down for the procedure (this is sometimes preferable, particularly if the patient is prone to vasovagal syncope). ◦ Ask the patient if they have any pain before continuing with the clinical procedure. ◦ Then choose the appropriate artery, if radial artery will be choosen then need to perform a simple test for better outcome.
  • 6. ◦ Allen test is a medical sign used in physical examination of arterial blood flow to the hands. ◦ The original test proposed by Allen is performed as follows: ◦ The patient is asked to clench both fists tightly for 1 minute at the same time. ◦ Pressure is applied over both radial arteries simultaneously so as to occlude them. ◦ The patient then opens the fingers of both hands rapidly, and the examiner compares the colour of both. The initial pallor should be replaced quickly by rubor.
  • 7.
  • 8. Indication ◦ 1) Respiratory failure. And assess its severity. ◦ 2) To monitor the patient on ventilator and assist weaning. ◦ 3) To Measure the acid-base level in the blood of people who are have heart failure, kidney failure, uncontrolled diabetes, sleep disorders, severe infections, or after a drug overdose. ◦ 4) Severe metabolic disturbance e.g. diabetic ketoacidosis ◦ 5) All critically ill patients.
  • 9. Parameters for ABG test ◦ 1) PH 7.35 to 7.45 in which from 7.35 to 7.39 is acidic and from 7.40 to 7.45 basic. ◦ 2) PCO2 35 to 45 mmhg ◦ 3) PO2 80 to 100 mmhg ◦ 4) SPO2 >90% ◦ 5) Bicarbonates 22 to 28 mEq/l
  • 10. ◦ Main 3 functions which are checked during ABG test ◦ - Respiratory function PCO2 ◦ - metabolic function HCO3 ◦ - Acid base balance PH.
  • 11. Main 4 disorders which will be found during ABG analysis ◦ 1 Respiratory Acidosis ◦ 2 Respiratory Alklosis ◦ 3 Metabolic Acidosis ◦ 4 Metabolic Alklosis
  • 12. Interpretation. ◦ Rules ◦ If PH HCO3 PCO2 ◦ Compensated Abnormal Abnormal / normal Abnormal / Normal ◦ Partly compensated Abnormal Abnormal Abnormal ◦ Fully compensated Normal Abnormal Abnormal.
  • 13. Henderson Hasselbach Equation ◦ PH ~ HCO3/ PCO2. ◦ HCO3 is metabolic component ◦ PCO2 is Respiratory component ◦ Acc. To this equation always consider abnormal values for eg. If the Hco3 is abnoraml and the pco2 is normal then we will say that the Metabolic acidosis or alkalosis.
  • 14. 4 Step method ◦ Step 1 – Use PH to determine the Acidosis and Akalosis ◦ Normal value of PH id 7.35 to 7.45 If ph is > 7.45 is alkalosis ◦ If ph value <7.35 Acidosis. ◦ Step 2 Interpretation of Equation and analysis Is either uncompensated, partly or fully compensated. ◦ Step 3 Determine respiratory effect ◦ Normal value 35 to 45 mmhg if > 45 acidosis ( low ph) , <35 alkalosis high ph) ◦ Or ◦ Determine Metabolic effect ◦ Normal value 22 to 28 mEq/l If > 28 Alkalosis , <22 acidosis. ◦ Step 4 If both the metabolic and respiratory factors are abnormal then minus the abnormal value from the normal value and considered greater one .
  • 15. Solve Example ◦ PH = 7.46 Ab. ◦ Pco2 = 44.4 normal ◦ HCO3 = 31.1 Ab. ◦ Pco2 113.2 Ab. ◦ Step 1 Alkalosis ◦ Step 2 Interpretation of formula PH~HCO3/PCO2 ◦ Uncompensated. ◦ Step 3 Metabolic ◦ Conclusion = Uncompensated metabolic alkalosis Hyperoxemia. ( 1)
  • 16. ◦ PH = 7.47 ◦ PCO2 = 48 mmhg ◦ HCO3 = 32 mmol/ l ◦ PO2 = 110 mmhg
  • 17. Causes of respiratory Acidosis ◦ Airway obstruction disease like ◦ COPD ◦ asthma ◦ CNS depression ◦ Neuromuscular impairment ◦ Ventilatory restriction ◦ Increased CO2 production: Due to increase intake of carbohydrates ◦ Incorrect mechanical ventilation settings
  • 18. Causes of respiratory alkalosis ◦ fever, pain, fear, anxiety, CVA, cerebral edema, brain trauma, brain tumor, CNS infection ◦ Hypoxemia or hypoxia: , low FiO2 ◦ pleural effusion, pneumonia, pneumothorax, pulmonary embolus ◦ Drugs, hormones: salicylates, catecholamines, progestins ◦ Pregnancy, liver disease, sepsis, hyperthyroidism ◦ Incorrect mechanical ventilation settings
  • 19. Causes of metabolic alkalosis ◦ Hypovolemia ◦ GI loss of H+ ◦ Vomiting, gastric suction, diarrhea . ◦ Renal loss H+ ◦ Loop and thiazide diuretics, post-hypercapnia ◦ Hypervolemia, ◦ Renal loss of H+: edematous states (heart failure, cirrhosis, nephrotic syndrome), excess ACTH, renal artery stenosis, bicarbonate administration
  • 20. Causes of metabolic acidosis ◦ Diarrhea, ileostomy, proximal colostomy . ◦ proximal RTA ◦ carbonic anhydrase inhibitor (acetazolamide) ◦ Renal tubular disease Chronic renal disease Distal RTA Aldosterone inhibitors or absence
  • 21. ◦ Arterial blood gas (ABG) values alone don't provide enough information to diagnose a problem. For example, they can't tell whether low levels are caused by lung or heart problems. Arterial blood gas values are most helpful when they are reviewed with other examinations and tests. ◦ An ABG test is often done for a person who is in the hospital because of severe injury or illness. The test can measure how well the person's lungs and kidneys are working and how well the body is using energy. ◦ An ABG test may be most useful when a person's breathing rate is increased or decreased or when the person has very high blood sugar (glucose) levels, a severe infection, or heart failure.
  • 22.
  • 23. Extubation ◦ Removal of tracheal tube or tracheotomy tube from the trachea is termed as Extubation.
  • 24. Creteria for extubation ◦ Approach ◦ Determine disease resolution and consider other factors ◦ Identify candidates for spontaneous breathing trial ◦ Perform spontaneous breathing trial ◦ Identify candidates for extubation ◦ Extubation and post-extubation care.
  • 25. DETERMINE DISEASE RESOLUTION ◦ Begins with the resolution of respiratory failure and/or the disease that prompted initiation of mechanical ventilation ◦ Criteria to define disease resolution are not defined ◦ A systemic approach emphasising objective surrogate markers of recovery ◦ Adequate oxygenation and gas exchange ◦ PaO2 >60mmHg on FiO2 <40% ◦ PEEP 5–8cmH2O ◦ CXR stable or improving
  • 26. ◦ absent or only low dose vasopressors/inotropes ◦ SBP>90mmHg. ◦ Stable cardiac rhythm ◦ No tacycardia ◦ No evidence of myocardial ischemia ◦ GCS>8 equivalent, some able to follow commands, some neither. ◦ No continuous sedative infusion or neuromuscular blockade ◦ no significant weakness (e.g. can lift head off pillow, raise arms in air for 15 seconds, clap hands) ◦ pain controlled
  • 27. No significant acidosis ◦ No electrolytes disturbance . ◦ adequate fluid status (not overloaded) ◦ abdominal pain/ distention controlled ◦ tolerating feeds ◦ Adequate hemoglobin ◦ Sepsis control.
  • 28. Identify candidates for spontaneous breathing trial ◦ Spontaneous breathing trials (SBT) are used to identify patients who are likely to fail liberation from mechanical ventilation. ◦ SBT is a test for determining readiness to breathe without a ventilator” ◦ Ideally, during an SBT we want to observe the patient under conditions of respiratory load that would simulate those following extubation. ◦ IDENTIFICATION OF PATIENTS SUITABLE FOR SBT ◦ Patients that pass the following daily ‘wean screen’ should undergo SBT: ◦ lung disease is stable/ resolving ◦ low FiO2 (< 50%) and PEEP (< 5-8cmH2O) requirement ◦ haemodynamic stability . ◦ able to initiate spontaneous breaths (good neuromuscular function) ◦ This indicates patients suitable for a spontaneous breathing trial, those who pass also to be assessed for extubation.
  • 29. Method ◦ SBT involves the following steps: ◦ It be conducted while the patient is still connected to the ventilator circuit. ◦ When using the ventilator a PS of 5 – 7 cmH2O and 1-5 cmH20 PEEP (so called ‘minimal ventilator settings’) will overcome increased work of breathing through the circuit (i.e. ETT) ◦ If still on the ventilator the patient should have ‘minimal ventilator settings” ◦ Initial trial should last 30 – 120 minutes ◦ If patient is not tolerate this, then Test will be negative (But) ◦ 80% of patients who tolerate this time can be permanently removed from the ventilator
  • 30. PERFORM SPONTANEOUS BREATHING TRIAL ◦ IDENTIFY PATIENTS READY FOR TRIAL OF EXTUBATION ◦ Key questions ◦ Awake or easily rousable? ◦ Able to follow commands? ◦ Minimal volume of respiratory secretions? ◦ Intact gag and cough reflex to prevent aspiration? (absent gag is normal in many people) ◦ Consider a cuff leak test to check for laryngeal oedema: ◦ Laryngeal edema reported in as many as 40% of prolonged intubations ◦ 5% patients experience severe upper airway obstruction following extubation ◦ can be detected by ‘cuff leak’ test
  • 31. Cuff leak test ◦ The cuff leak test is used to predict risk of post-extubation stridor in intubated patients ◦ Use and interpretation of the test needs to take into account the overall context of the patient’s condition and the management implications. ◦ Procedure ◦ Suction endotracheal and oral secretions and set the ventilator in the assist control mode with the patient receiving volume-cycled ventilation ◦ With the cuff inflated, record displayed inspiratory and expiratory tidal volumes to see whether these are similar ◦ Deflate the cuff ◦ Directly record the expiratory tidal volume over the next six breathing cycles as the expiratory tidal volume will reach a plateau value after a few cycles ◦ Average the three lowest values ◦ The difference between the inspiratory tidal volume (measured before the cuff was deflated) and the averaged expiratory tidal volume (after cuff deflation) is the cuff leak volume
  • 32. ◦ failed cuff-leak test ◦ was defined as a leak volume of less than 110 mL, or 15.5% ◦ of exhaled volume before cuff deflation. ◦ EXTUBATION AND POST-EXTUBATION CARE ◦ Monitor closely for Laryngospasm and Post-extubation stridor — reintubation is not always need ◦ Consider high flow nasal prongs or non-invasive ventilation to treat or prevent post- extubation respiratory failure
  • 33. Extubation failure ◦ primary types of failure. “the inability to tolerate removal of the translaryngeal tube. “ liberation failure is used to refer to the inability to tolerate spontaneous ventilation without mechanical support. Causes of failure 1) Laryngospasm 2) Postobstructive Pulmonary Edema 3) Laryngeal Edema 4) Airway injury.
  • 34. Treatment of Extubation Failure ◦ The onset of respiratory distress following extubation ◦ should alert the clinician that the patient is failing extuba- ◦ tion. Hypercapnia, hypoxia, and abdominal breathing are ◦ all signs that re-intubation may be necessary. Severe post- ◦ extubation stridor and an inability to manage secretions ◦ are additional indications for re-intubation. ◦ Patients who fail extubation have an increased mortality ◦ rate compared with patients who are successfully extu- ◦ bated on the first attempt
  • 35. or patients who fail their first ◦ breathing trial are not extubated. NIV has not been shown to reduce ◦ the rates of re-intubation, and it can increase mortality by ◦ delaying re-intubation.